Breast Cancer Coverage from Every Angle

Hope Rugo, MD, on Clinical Implications of New Findings on the Benefits of Sacituzumab Govitecan-hziy in Advanced Breast Cancer

Posted: Monday, June 27, 2022

Hope Rugo, MD, of the University of California, San Francisco, discusses new data from the phase III TROPiCS-02 trial. Dr. Rugo also focuses on practical clinical issues such as whether the results of the trial represent a potentially practice-changing option for women with HER2-low breast cancer, which patients with breast cancer are ideal candidates for sacituzumab govitecan-hziy, and how to give and monitor this agent more safely and manage adverse events so patients can stay on therapy longer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.